Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a drug that can trigger CRS. Recruitment is progressing well with plans to expand to more clinical sites. Poolbeg raised £3.5 million in July to fund this and another drug trial, and is in talks with partners about POLB 001's development.
Poolbeg Pharma's cancer side-effect trial is the subject, with Pluang's health sector data providing market context. As of Sep 28, 2026 14:21 WIB, 40 of 100 priced US health stocks rose while 51 fell. Notable movers include XRAY at USD 9.40 down 3.89%, AMLX at USD 29.50 down 3.61%, and ENVB at USD 1.51 down 3.51%.
NEAR Protocol's price surged from below $2 to over $5, peaking near $5.42 before a slight pullback, fueled by the anticipation of Bitwise's U.S. spot NEAR ETF launch. Technical indicators like RSI at 79.91 show overbought conditions, while MACD remai...
Bitcoin is trading around $82,949, about 5% below its 2026 start, with potential to reclaim $87,500 and end the year in the green. Spot buying has increased, pushing prices toward $86,000, supported by strong institutional demand via U.S. spot Bitcoi...
Cardano (ADA) price remains just under the $0.26 resistance after an 11.5% weekly rise, showing signs of consolidation. Futures market data presents mixed signals with a low long-to-short ratio suggesting bearish sentiment, while positive funding rat...
SoFi Bank has launched SoFiUSD, its own stablecoin, to settle over $25 billion annually through Mastercard's global payments network, moving from pilot to live production. This bank-issued stablecoin is redeemable 1:1 for U.S. dollars and backed by c...
The Liberty All-Star Growth Fund (ASG), a closed-end fund investing across market caps, is currently trading at a significant discount due to both widening discount levels and relatively weak portfolio performance. While the fund has a stronger long-...
